Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First Tissue-Agnostic Drug Approval Issued

6 Jun 2017

Abstract excerpt

The PD-1 inhibitor pembrolizumab received accelerated approval for adult and pediatric patients with solid tumors that are mismatch repair-deficient or microsatellite instability-high. This is the first time the FDA has greenlighted a drug based not on tumor type, but on a common biomarker.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic factors in colorectal cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28583911
DOI: 10.1158/2159-8290.cd-nb2017-078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First Tissue-Agnostic Drug Approval IssuedPMID 28583911Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

Tissue-Agnostic Drug Development: A New Path to Drug ApprovalSemantic proximity Read ↗

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.Semantic proximity Read ↗

If it's a target, it's a pan-cancer target: Tissue is not the issue.Semantic proximity Read ↗

When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.Semantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesSemantic proximity Read ↗

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.Semantic proximity Read ↗

Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity Read ↗

Impact of tissue-agnostic approvals on management of primary brain tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.